BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32945554)

  • 1. Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma.
    Rieken J; Bernard V; Witte HM; Peter W; Merz H; Olschewski V; Hertel L; Lehnert H; Biersack H; von Bubnoff N; Feller AC; Gebauer N
    Br J Haematol; 2021 Apr; 193(1):138-149. PubMed ID: 32945554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with
    Olschewski V; Witte HM; Bernard V; Steinestel K; Peter W; Merz H; Rieken J; Biersack H; von Bubnoff N; Feller AC; Gebauer N
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.
    Westmoreland KD; Montgomery ND; Stanley CC; El-Mallawany NK; Wasswa P; van der Gronde T; Mtete I; Butia M; Itimu S; Chasela M; Mtunda M; Kampani C; Liomba NG; Tomoka T; Dhungel BM; Sanders MK; Krysiak R; Kazembe P; Dittmer DP; Fedoriw Y; Gopal S
    Int J Cancer; 2017 Jun; 140(11):2509-2516. PubMed ID: 28268254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma.
    Graef CM; Gödel P; Falderbaum P; Balke-Want H; Simon F; Sieg N; Naendrup JH; Neumann MA; Gillessen S; Bröckelmann PJ; Eichenauer DA; Borchmann P; von Tresckow B; Heger JM
    Eur J Haematol; 2022 May; 108(5):403-412. PubMed ID: 35090068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma.
    Keane C; Gould C; Jones K; Hamm D; Talaulikar D; Ellis J; Vari F; Birch S; Han E; Wood P; Le-Cao KA; Green MR; Crooks P; Jain S; Tobin J; Steptoe RJ; Gandhi MK
    Clin Cancer Res; 2017 Apr; 23(7):1820-1828. PubMed ID: 27649554
    [No Abstract]   [Full Text] [Related]  

  • 6. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
    Kodet R; Mrhalová M; Stejskalová E; Kabícková E
    Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.
    Miyauchi K; Urano E; Yoshiyama H; Komano J
    Cancer Sci; 2011 Jun; 102(6):1236-41. PubMed ID: 21392167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV
    Hernández DM; Valderrama S; Gualtero S; Hernández C; López M; Herrera MV; Solano J; Fiorentino S; Quijano S
    Front Immunol; 2018; 9():2291. PubMed ID: 30337929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
    Thomas DA; O'Brien S; Faderl S; Manning JT; Romaguera J; Fayad L; Hagemeister F; Medeiros J; Cortes J; Kantarjian H
    Curr Hematol Malig Rep; 2011 Mar; 6(1):58-66. PubMed ID: 21191675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
    Xiao J; Du S; Dai G; Gao G; Yang D; Zhao H
    Sci Rep; 2017 May; 7(1):1905. PubMed ID: 28507339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH.
    Chuang SS; Ye H; Du MQ; Lu CL; Dogan A; Hsieh PP; Huang WT; Jung YC
    Am J Clin Pathol; 2007 Oct; 128(4):558-64. PubMed ID: 17875505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort.
    Schommers P; Hentrich M; Hoffmann C; Gillor D; Zoufaly A; Jensen B; Bogner JR; Thoden J; Wasmuth JC; Wolf T; Oette M; Müller M; Esser S; Vehreschild JJ; Fätkenheuer G; Wyen C
    Br J Haematol; 2015 Mar; 168(6):806-10. PubMed ID: 25403997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.
    Gormley RP; Madan R; Dulau AE; Xu D; Tamas EF; Bhattacharyya PK; LeValley A; Xue X; Kumar P; Sparano J; Ramesh KH; Pulijaal V; Cannizzaro L; Walsh D; Ioachim HL; Ratech H
    Am J Clin Pathol; 2005 Nov; 124(5):790-8. PubMed ID: 16203284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
    Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
    Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection.
    Kamga L; Gil A; Song I; Brody R; Ghersi D; Aslan N; Stern LJ; Selin LK; Luzuriaga K
    PLoS Pathog; 2019 Nov; 15(11):e1008122. PubMed ID: 31765434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma.
    Gonin J; Larousserie F; Bastard C; Picquenot JM; Couturier J; Radford-Weiss I; Dietrich C; Brousse N; Vacher-Lavenu MC; Devergne O
    PLoS One; 2011; 6(9):e24617. PubMed ID: 21931777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
    Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
    Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-viral
    Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
    Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.